首页> 外文会议>International Conference on Advances in Engineering, Science and Management >Designing of de novo dual inhibitors for Bcl-XL and Mcl-1 of Bcl2-family proteins by computational methods
【24h】

Designing of de novo dual inhibitors for Bcl-XL and Mcl-1 of Bcl2-family proteins by computational methods

机译:通过计算方法设计BCL-XL和Bcl2-Family蛋白的Bcl-XL和Mcl-1的De Novo双重抑制剂

获取原文

摘要

Anti-apoptotic proteins such as Bcl-XL and Mcl-1 have been reported to be over expressed in most cancer forms and consequently, designing dual inhibitors to the proteins is becoming an important strategy in cancer chemotherapy. Interestingly, the Bcl-XL and Mcl-1 show differential binding affinities with BH3-only peptides of Bim and NOXA, notwithstanding their similar three-dimensional folds. The structural determinants for the differential interactions of the proteins with the BH3-only peptides have been scrutinized using molecular docking and temperature-dependent dynamic studies. The comprehensive analysis of the data from the studies paved a way of designing dual inhibitors to the proteins, on the basis of the chemical structures of ABT-737, which is a highly potent inhibitor to the Bcl-XL. The unique feature of this approach on designing the dual inhibitors to the anti-apoptotic proteins have also been brought into detail through a comparative analysis with a few existing strategies reported on the same line in the literature.
机译:据报道,抗凋亡蛋白如Bcl-X1和Mcl-1,以在大多数癌症形式中表达,因此,将双重抑制剂设计为蛋白质正在成为癌症化疗的重要策略。有趣的是,Bcl-XL和MCL-1显示差异的结合亲和力与BH3的BH3肽的BH3和NOXA,尽管它们类似的三维折叠。使用分子对接和温度依赖性动态研究仔细仔细地仔细地仔细仔细地仔细仔细地仔细仔细地审查了蛋白质与BH3肽的差异相互作用。根据ABT-737的化学结构,从研究中的数据综合分析铺设了一种将双重抑制剂设计为蛋白质的方法,这是BCL-XL的高效抑制剂。这种方法在设计双抑制剂对抗凋亡蛋白的独特特征也通过对比较分析进行了详细的详细,其中一些现有策略在文献中的同一线上报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号